COMMUNIQUÉS West-GlobeNewswire

PCI Biotech: Last day of subscription period

03/10/2018 - 08:00

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER [...]

Director/PDMR Shareholding

03/10/2018 - 08:00

DXS INTERNATIONAL PLC Director Dealing The Board of DXS International plc (the “Company”), the NEX quoted clinical decision support developer and supplier of clinical decision support systems is pleased to confirm that [...]

Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma

03/10/2018 - 08:00

Overall response rate data from the (RXE 1 ) Phase II study conducted in the US and Sweden met its primary end points and treatment with Doxophos Vet was generally well tolerated. Oasmia’s assessment is that the [...]

Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2018

03/10/2018 - 07:30

LYON, France, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: [...]

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 30 septembre 2018

03/10/2018 - 07:30

LYON, France, 03 oct. 2018 (GLOBE NEWSWIRE) -- Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Lyon - France Places de cotation : Euronext Paris de Euronext (Compartiment B - Code ISIN : [...]

Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals

03/10/2018 - 07:16

Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to partner with like-minded innovators [...]

ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)

03/10/2018 - 07:00

Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety profile not different from placebo in IMPLANT 2 European MAA submission confirmed to be targeted [...]

GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million

03/10/2018 - 02:04

LONDON and CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel [...]

Telix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging

03/10/2018 - 02:00

INDIANAPOLIS and COLUMBUS, Ohio, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (US) Inc. (“Telix USA”), a subsidiary of Telix Pharmaceuticals Limited (ASX:TLX), a clinical-stage biopharmaceutical company [...]

Pain Therapeutics Announces Investor Call to Provide Strategic Update

03/10/2018 - 01:48

Call to be Held on Thursday, October 4th, 10:00 AM Eastern Time AUSTIN, Texas, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it will host a [...]

Dr. Brian Buinewicz Introduces EMSCULPT® to the Long Island Area

03/10/2018 - 01:00

Now, patients can simultaneously build muscle and burn fat for outstanding cosmetic results DOYLESTOWN, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Dr. Brian Buinewicz of Buinewicz Plastic Surgery has been offering patients [...]

Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)

03/10/2018 - 00:37

– Modernized Tetracycline for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) specifically designed to overcome tetracycline resistance – – First and [...]

Genesis HealthCare Announces Completed Divestiture of 16 Facilities in Texas

03/10/2018 - 00:27

KENNETT SQUARE, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare (Genesis, or the Company) (NYSE: GEN), one of the largest post-acute care providers in the United States, today announced it completed the sale [...]

Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage

02/10/2018 - 22:30

COLUMBIA, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, [...]

GenMark Diagnostics Announces FDA Submission of its ePlex Blood Culture Identification Gram-Negative and ePlex Blood Culture Identification Fungal Pathogen Panels

02/10/2018 - 22:14

Submissions Now Complete for All Three ePlex Molecular Multiplex Panels Designed for the Diagnosis and Management of Bloodstream Infections That Can Lead to Sepsis CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- [...]

Nightstar Announces Closing of Public Offering and Full Exercise of Underwriters’ Option

02/10/2018 - 22:05

WALTHAM, Mass. and LONDON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the [...]

Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting

02/10/2018 - 22:05

SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that two abstracts – one addressing clinical results with the company’s pan-caspase inhibitor, emricasan, and one [...]

Novavax to Highlight RSV Program Data at Two Upcoming Meetings

02/10/2018 - 22:05

GAITHERSBURG, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 [...]

SELLAS to Present Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

02/10/2018 - 22:01

NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer [...]